Notes: MDV 3100 is a non-steroidal androgen receptor antagonist (IC50 = 36 nM).{24601,24600} It reduces the efficiency of nuclear translocation of the androgen receptor and impairs both its binding to DNA and the recruitment of coactivators.{24601} It is orally available and induces tumor regression in mouse models of castration-resistant human prostate cancer.{24601} It has applications in advanced cancers that remain dependent on androgen receptor signaling even in the absence of androgen.{24599}